Cara Therapeutics just closed on Monday with a $145.5 million stock offering. This is their third major public offering in the last 2.5 years and they plan to use the proceeds to fund the work they are doing on a new drug they are submitting to the FDA for Korsuva injections. The funding will help to support the clinical programs for an oral version of Korsuva
Korsuva will become their first drug to make it to market. They are based in Stamford, Connecticut.